COMPANY:

BostonGene

"BostonGene...announced today the launch of a collaboration aimed at discovering biomarkers for immunotherapy (IO) treatment response and treatment-related toxicity in advanced non-small cell lung cancer (NSCLC) patients....This study will evaluate the tumor microenvironment (TME) utilizing the BostonGene Tumor Portrait test in tissue samples collected before EGFR-TKI treatment and before ICI administration in patients with EGFR-positive lung adenocarcinoma."

"BostonGene...announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA. BostonGene will exhibit at booth #847....This study shows the feasibility and utility of comprehensive molecular profiling to match patients to WES-informed treatments within a clinically relevant time frame. The high rate of additional actionable findings identified by BostonGene’s analytical platform suggest comprehensive testing may offer benefit over traditional targeted panels in solid tumor patients."

"BostonGene...today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory. ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial. ComboMATCH aims to overcome drug resistance to single-drug therapies by developing targeted drug combinations. NCI is a part of the National Institutes of Health....A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies."

"BostonGene...announced it will participate in the United States and Canadian Academy of Pathology (USCAP) 113th Annual Meeting...BostonGene to showcase the power of next-generation multi-platform AI-driven analytics, paving the way for novel cancer therapeutics and showcasing RNA sequencing's crucial role in validating biomarkers assessed pathologically..."

"BostonGene...today announced the publication of the manuscript....The research's key findings included identifying unique histological patterns such as stromal desmoplasia and follicular growth pattern alterations observed before first progression and relapse in FL patients. Additional results provide a comprehensive characterization of the genomic and transcriptomic landscapes of tumor B cells, uncovering diverse genetic lesions and alterations in pathways associated with immune escape, apoptosis resistance, and extracellular matrix remodeling. Utilizing single-cell resolution profiling, the research revealed distinct populations of B cells, T cells, myeloid cells, and stromal cells within FL lymph nodes, shedding light on their spatial distribution within the tumor microenvironment."

"Transgene..., NEC Corporation...and BostonGene Corporation...announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therapeutic vaccine for patients with head and neck cancers. BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services. The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture."

"BostonGene...announced today that it will participate in the 21st Japanese Society of Medical Oncology (JSMO) Annual Meeting. The research conference will be held at the Nagoya Congress Center from February 22 to 24, bringing together a diverse tumor-agnostic academic society focused on pharmacologic therapy with the objective of delivering research to enhance the quality of life for all cancer patients....BostonGene will deliver presentations demonstrating the utility of integrated genomic and transcriptomic profiling in identifying clinically relevant alterations for treatment decision-making and describe the development of AI-based analytical tools and pipelines to comprehensively understand each patient’s disease."

P1 | N=62 | NCT03152318 | "BostonGene...today announced the online publication...in Nature...Utilization of immunotherapy for GBM has been challenging due to the scarcity of infiltrating antitumor lymphocytes caused by a highly immunosuppressive or 'lymphocyte-depleted' tumor microenvironment (TME)....The results demonstrated a single injection of CAN-3110 activated an antitumor immune response in GBM, inducing defined changes in T cell repertoires and tumor transcriptomic signatures. These findings are evidence that intralesional onolytic viruses can convert the immunosuppressive GBM TME to an immunoactivated state that is more responsive to immunotherapy."

"BostonGene...announced...that it will participate in and present at the SLAS2024 International Conference and Exhibition on February 3 – 7, 2024, in Boston, MA at the Boston Convention & Expo Center. This global event brings together a diverse community of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to transform research."

"BostonGene...announced a master agreement with Duke University School of Medicine...to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers. The strategic partnership allows Duke physicians and researchers to leverage BostonGene's expertise to drive the molecular and cellular characterization of the patient's tumor, microenvironment and immune system and test its predictive value in response to treatment. For cancer patients undergoing treatment at Duke University, including those participating in clinical trials, BostonGene will provide state-of-the-art analytics, interpretation and visualization of big data obtained from analysis of patients’ genomic, transcriptomic, cell phenotyping, proteomic and imaging studies."

"BostonGene...today announces a collaboration with Prisma Health aimed at advancing the understanding of rare tumors by characterizing the tumor microenvironment (TME), mutational landscape and host immune profiles of patients treated with immune checkpoint inhibitors....In collaboration with Prisma Health’s Rare Tumor Center, BostonGene will analyze tissue and peripheral blood from rare cancer solid-tumor patients to understand the molecular underpinnings of immune-activating drugs commonly used to enhance a person's innate mechanisms to fight cancer. BostonGene will perform detailed analyses of primary tumors and immunoprofiling of matched peripheral blood collected during this cohort of the trial, which is currently enrolling patients."

"BostonGene...announced the online publication of the manuscript, 'Spatial Mapping of Human Hematopoiesis at Single Cell Resolution Reveals Aging-Associated Topographic Remodeling,' in Blood, the most cited peer-reviewed publication in the field of hematology."

"BostonGene...and the Sarcoma Oncology Center, announced a collaboration to expedite the availability of DeltaRex-G. This groundbreaking platform therapy, authorized by the FDA's Center for Biologics Evaluation and Research (CBER), holds immense promise for patients battling advanced pancreatic cancer, osteosarcoma, soft tissue sarcoma, and breast cancer. The designation of DeltaRex-G, a CCNG1 inhibitor, as a platform therapy with the potential to incorporate other FDA-approved drugs, was enabled by BostonGene's pivotal identification of elevated CCNG1 levels in these different cancer types."

"BostonGene...announced the selection of four abstracts for oral presentation, four abstracts as poster presentations, and two abstracts for online publication at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 9-12, 2023, in San Diego, California and virtually....This presentation highlights results from the Phase 2 ELARA trial that show efficacy, safety, pharmacokinetic, and exploratory biomarker analyses in relapsed/refractory follicular lymphoma patients treated with tisagenlecleucel after a median follow-up of more than 3 years."

"BostonGene...today announced that two abstracts have been accepted for poster presentations for the 2023 San Antonio Breast Cancer Symposium (SABCS), which will be held December 5 - 9, 2023, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. BostonGene will also exhibit at booth 1515."

"BostonGene...announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 – 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT."

"BostonGene...announced that three research studies done in collaboration with Weill Cornell Medicine will be presented as poster presentations at the 20th International Cancer Genome Consortium (ICGC) Scientific Workshop/ 7th Accelerating Research in Genomic Oncology (ARGO) meeting."

"BostonGene...announced a collaboration to support the Phase I/II study of LCB84, a TROP2-directed ADC, in patients with advanced cancers. This first-in-human study is being conducted at leading cancer institutions in the US and Canada to evaluate the safety and preliminary efficacy of LCB84, both as a single-agent therapy and in combination with an immune checkpoint inhibitor (anti-PD-1 antibody)....BostonGene will serve as the study’s central laboratory and analytic partner for exploratory biomarkers, performing in-depth, multi-omic profiling of patients’ tumor tissue and blood samples, including whole-exome sequencing (WES), whole-transcriptome sequencing (RNAseq) of tumor tissue from matched tumor biopsies on the study, and immunoprofiling to identify hundreds of different cell types from a single blood sample."

"BostonGene...announced the Company will present four posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 at the San Diego Convention Center in San Diego, CA....This study showed that the IHC results of five promising ADC targets (HER3, HER2, TROP2, Nectin4, and aFLR) correlated with their RNA sequencing (RNA-seq) gene expression values, highlighting the potential use of RNA-seq to detect ADC targets....Transcriptomic analysis of human papillomavirus (HPV)+ head and neck squamous cell carcinomas (HNSCCs) revealed a disparity in underlying mechanisms of ICI response, particularly related to the tumor microenvironment (TME), between HPV- and HPV+ HNSCC patients....The results showed that the TME subtypes and CD8+ T cell infiltration were associated with overall and progression-free survival, indicating their potential as predictive biomarkers for immunotherapy response."

"BostonGene...announced its abstract has been accepted for poster presentation at the 2023 CTOS Annual Meeting being held November 1-4, 2023, in Dublin, Ireland."

"BostonGene...and FibroFighters...have announced a collaboration to advance clinical care for FLC patients. FLC is a rare form of liver cancer typically diagnosed in adolescents and young adults under 40. FibroFighters has partnered with BostonGene to leverage their AI and molecular profiling techniques to gain deeper insights and identify targeted treatments. The partnership focuses on strategies to drive patient-centric engagement. FibroFighters will actively promote access to the BostonGene Tumor Portrait test, a revolutionary diagnostic test that unveils critical information about each tumor, including immune microenvironment properties, actionable mutations, biomarkers for therapy response, and recommended treatment strategies."

"BostonGene...announced the BostonGene and Exigent Genomic INsight (BEGIN) Study, designed to demonstrate the clinical benefits of using BostonGene Tumor Portrait^™ test for advanced cancer patients in a community setting. The BEGIN Study will validate improved patient outcomes by tailoring treatments based on combined WES and RNA-seq coupled with AI-powered analytics....As part of the BEGIN study, BostonGene will perform comprehensive analysis using the BostonGene Tumor Portrait^TM test, including DNA whole exome (WES) and RNA transcriptome (RNAseq) sequencing, on patient tumor samples from participating Exigent sites. The study aims to determine the utility and frequency of actionable findings identified by a comprehensive sequencing approach in advanced cancer patients in a real-world setting. The trial will also assess the impact of the BostonGene Tumor Portrait^TM test findings on treatment decisions..."

"BostonGene, a leading provider of AI-based molecular and immune profiling solutions, announced today that it will present three abstracts at ESMO Congress 2023....The event will be held on October 20 - 24, 2023, in Madrid, Spain, at the IFEMA MADRID. BostonGene will also exhibit in Hall 5, booth 550."

"BostonGene...announced...that it will participate in and present at the Festival of Genomics & Biodata...In this session, BostonGene will discuss how advances in next-generation sequencing have generated a wealth of unmined genomic data across myriad fields, including oncology."

"BostonGene...today announced a master agreement with Johns Hopkins University School of Medicine (JHUSOM) to collaborate on multiple clinical research projects. The agreement allows BostonGene and JHUSOM to further identify and validate novel precision medicine approaches....JHUSOM will work with BostonGene on the molecular characterization study of the patient's tumor, microenvironment and immune system and its predictive value in response to treatment. BostonGene’s solution will provide JHUSOM with detailed analysis, interpretation and visualization of big data obtained from cancer patient’s genomic, transcriptomic, proteomic and imaging studies."

"BostonGene...announced...that it will participate in the 82nd Annual Meeting of the Japanese Cancer Association (JCA). The event, to be held at Pacific Convention Plaza Yokohama from September 21 – September 23, focuses on all aspects of cancer research, including basic, clinical and translational research into the etiology, prevention, diagnosis, and treatment of cancer...BostonGene will deliver presentations demonstrating the integration of our innovative solutions encompassing multiple AI-based molecular and immune profiling techniques that analyze the tumor, tumor microenvironment, and immune system to comprehensively understand each patient’s disease."

"BostonGene today announced an agreement with Hokkaido University Hospital to drive the discovery, validation and implementation of a groundbreaking stratification protocol for HER2-positive breast cancer patients...In this study, BostonGene will apply its genomics pipeline to reveal key tumor drivers, including immune microenvironment properties and genomic biomarkers of response to diverse therapies."

"BostonGene...NEC Corporation...and Japan Industrial Partners...announced the formation of BostonGene Japan Inc., a Tokyo-based joint venture aimed at advancing personalized medicine and dramatically improving patient outcomes. The new company will utilize BostonGene’s high-complexity molecular technology and advanced biocomputational algorithms, including BostonGene Tumor Portrait™ tests, to accelerate the development and validation of novel precision medicine approaches."

"BostonGene announced...that it will participate in and present at the 11th Annual Immuno-Oncology Summit, the leading annual meeting focusing on the next wave of biotherapeutics, advances in technologies, and the valuable exchange of high-quality research from all disciplines of immuno-oncology, which is being held August 7 – 9, 2023 in Boston, MA...In this session, BostonGene will discuss how comprehensive profiling of a patient’s disease for therapy selection and stratification for IO clinical trials improves outcomes using CLIA-certified advanced whole exome and whole transcriptome sequencing paired with best-in-class analytics."

"BostonGene announced...that it will participate in and present at the 6th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference on June 22 – 23 in Boston, MA...This session will address how BostonGene bridges this gap by providing a comprehensive profile or portrait of a patient’s disease for therapy selection and stratification for IO clinical trials."

"BostonGene...announced that four abstracts have been accepted for poster presentations and two abstracts have been accepted for online publication for the 2023 ASCO Annual Meeting (ASCO), which will be held June 2 – 6, 2023, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth 28155."

"BostonGene announced...the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics solutions that provide a holistic view of a patient’s disease by integrating multiple AI-based molecular and immune profiling techniques that analyze tumor, microenvironment, and host immunity. The new offerings, in addition to the BostonGene Tumor Portrait test, will support and improve the efficacy of clinical trials and research and development efforts. The solutions will ensure clinical trial populations are well-defined and representative, assess the safety and effectiveness of treatment while monitoring side effects and select the appropriate patient populations for myriad therapies."

"BostonGene today announced a collaboration with Sylvester Comprehensive Cancer Center to study the tumor microenvironment (TME) and mutational landscape of patients with high-grade B-cell lymphoma (HGBCL)....The study will analyze the TME and translocation status in patients with HGBCL, an aggressive type of B-cell non-Hodgkin lymphoma (NHL) to study how genomics can shape the tumor microenvironment and correlate the genomic landscape and expression differences with clinical outcomes. In this collaboration, BostonGene will perform next-generation sequencing, including whole exome and whole transcriptomic analyses of primary tumors collected from HGBCL patients treated at Sylvester."

"BostonGene announced...that as part of its ongoing commitment to improving the diagnosis and personalized treatment recommendations for cancer patients, it will participate in and present at PEGS Boston Summit on May 15 – 19, 2023, at the Hynes Convention Center. The event is the leading biologics event covering all aspects of biologic drug development with in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytics, immunogenicity, and more. BostonGene will also exhibit at booth #228."

"BostonGene Corporation has announced a major research collaboration with Australia’s Mater Research to discover novel diagnostic biomarkers of follicular lymphoma and ultimately improve treatment for patients in the advanced stages of the disease....Led by Honorary Senior Research Fellow Dr Joshua Tobin, Mater Research will work with US-based molecular and immune profiling leader BostonGene to analyze hundreds of follicular lymphoma (FL) biopsy samples and assess the prognostic impact of changes in immune function within each tumor. BostonGene will provide whole transcriptome sequencing (RNA-seq), comprehensive spatial proteomics and advanced analytics to develop clinically applicable RNA and protein-based biomarkers for use in clinical practice."

"BostonGene today announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, which will be held from April 14 – 19, at the Orange County Convention Center in Orlando, FL....BostonGene will present posters that describe the development of novel assays and analytical tools and pipelines to advance precision oncology, including our liquid biopsy platform and cancer of unknown primary (CUP) classifier. BostonGene will also demonstrate ability of comprehensive molecular profiling to identify clinically relevant alterations that can be utilized for treatment decision-making. The presentations highlight the application of BostonGene’s innovative technologies to improve the diagnosis and personalized treatment recommendations for cancer patients."

"BostonGene...announced a collaboration with Little Warrior Foundation to drive the discovery, validation, and implementation of novel liquid biopsy solutions into sarcoma clinical practice."